Contraindicated Use of Cisapride, JAMA, vol.284, issue.23, pp.3036-3045, 2000. ,
DOI : 10.1001/jama.284.23.3036
Le syndrome du QT long acquis. Thèse d'exercice : Médecine : Université de Nantes, 2007. ,
What Clinicians Should Know About the QT Interval, JAMA, vol.289, issue.16, pp.2120-2127, 2003. ,
DOI : 10.1001/jama.289.16.2120
Mechanisms of Drug Induced QT Interval Prolongation, Current Drug Safety, vol.5, issue.1, pp.44-53, 2010. ,
DOI : 10.2174/157488610789869247
Drug induced QT prolongation and torsades de pointes, Heart, vol.89, issue.11, pp.1363-72, 2003. ,
DOI : 10.1136/heart.89.11.1363
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1767957
Drug-Induced Prolongation of the QT Interval, N Engl J Med, vol.350, issue.10, pp.1013-1035, 2004. ,
Ventricular arrythmias. Drug-induced diseases: prevention, detection, and management, pp.491-515, 2010. ,
Drug-induced long QT and torsade de pointes: recent advances, Current Opinion in Cardiology, vol.22, issue.1, pp.39-43, 2007. ,
DOI : 10.1097/HCO.0b013e32801129eb
Terminologie -Torsades de pointes ,
Torsade de Pointes, p.6, 2015. ,
Exemple de torsade de pointe chez un patient avec prolongation congénitale de l'intervalle QT, 2015. ,
Cellular Mechanisms of Torsade de Pointes, Novartis Found Symp, vol.266, pp.204-228, 2005. ,
DOI : 10.1002/047002142X.ch16
ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death, European Heart Rhythm Association, pp.247-346, 2006. ,
DOI : 10.1016/j.jacc.2006.07.010
Case ascertainment and estimated incidence of drug-induced long-QT syndrome: study in Southwest France, British Journal of Clinical Pharmacology, vol.105, issue.K, pp.386-95, 2008. ,
DOI : 10.1111/j.1365-2125.2008.03229.x
URL : https://hal.archives-ouvertes.fr/inserm-00409223
QTDrugs list. https://www.crediblemeds.org/index, p.32806, 2015. ,
Ventricular arrythmias. Drug-induced diseases: prevention, detection, and management, pp.491-515, 2010. ,
Drug- and non-drug-associated QT interval prolongation, British Journal of Clinical Pharmacology, vol.115, issue.1, pp.16-23, 2010. ,
DOI : 10.1111/j.1365-2125.2010.03660.x
Cardiotoxicit?? des??antihistaminiques de??deuxi??me g??n??ration, Revue Fran??aise d'Allergologie et d'Immunologie Clinique, vol.46, issue.4, pp.392-401, 2006. ,
DOI : 10.1016/j.allerg.2006.05.001
Torsade de Pointes Due to Noncardiac Drugs, Medicine, vol.82, issue.4, pp.282-90, 2003. ,
DOI : 10.1097/01.md.0000085057.63483.9b
TRIad: Foundation for Proarrhythmia (Triangulation, Reverse Use Dependence and Instability), Novartis Found Symp, vol.266, pp.235-50, 2005. ,
DOI : 10.1002/047002142X.ch18
Extracellular Potassium Modulation of Drug Block of IKr : Implications for Torsade de Pointes and Reverse Use-Dependence, Circulation, vol.93, issue.3, pp.407-418, 1996. ,
DOI : 10.1161/01.CIR.93.3.407
Action Potential and QT Prolongation Not Sufficient to Cause Torsade de Pointes: Role of Action Potential Triangulation, Journal of Cardiovascular Electrophysiology, vol.18, issue.2, pp.204-209, 2007. ,
DOI : 10.1016/S0008-6363(99)00035-8
Chronic Amiodarone Evokes No Torsade de Pointes Arrhythmias Despite QT Lengthening in an Animal Model of Acquired Long-QT Syndrome, Circulation, vol.104, issue.22, pp.2722-2729, 2001. ,
DOI : 10.1161/hc4701.099579
Amiodarone-associated Proarrhythmic Effects: A Review with Special Reference to Torsade de Pointes Tachycardia, Annals of Internal Medicine, vol.121, issue.7, pp.529-564, 1994. ,
DOI : 10.7326/0003-4819-121-7-199410010-00009
Allongement de l'intervalle QT/QTc : Contenu des monographies de produit, p.6, 2015. ,
Female Gender as a Risk Factor for Torsades de Pointes Associated With Cardiovascular Drugs, JAMA: The Journal of the American Medical Association, vol.270, issue.21, pp.2590-2597, 1993. ,
DOI : 10.1001/jama.1993.03510210076031
Cardiac ventricular repolarization reserve: a principle for understanding drug-related proarrhythmic risk, British Journal of Pharmacology, vol.111, issue.1, pp.14-36, 2011. ,
DOI : 10.1111/j.1476-5381.2011.01367.x
Recent advances in understanding sex differences in cardiac repolarization, Progress in Biophysics and Molecular Biology, vol.94, issue.3, pp.265-319, 2007. ,
DOI : 10.1016/j.pbiomolbio.2005.05.010
Interactions médicamenteuse et risque de torsades de pointes, Pharmactuel, vol.38, issue.3, pp.134-143, 2005. ,
What Clinicians Should Know About the QT Interval, JAMA, vol.289, issue.16, pp.2120-2127, 2003. ,
DOI : 10.1001/jama.289.16.2120
php?lng=FR&data_id=658&Disease_Disease_Search_diseaseGroup=syn drome-du-qtlong&Disease_Disease_Search_diseaseType=Pat&Maladie(s )/groupes%20de%20maladies= Syndrome-du-QT-long-familial--Syndrome-du-QT-long-congenital-&title=Syndrome-du- QT-long-familial--Syndrome-du-QT-long-congenital-&search=Disease_Search_Simple ,
Cardiac ventricular repolarization reserve: a principle for understanding drug-related proarrhythmic risk, British Journal of Pharmacology, vol.111, issue.1, pp.14-36, 2011. ,
DOI : 10.1111/j.1476-5381.2011.01367.x
Ordre national des pharmaciens. Dispensation des produits de santé. www.ordre.pharmacien.fr, 2015. ,
De la prescription à la dispensation : état des connaissances des prescripteurs, intérêt de la relation médecin-pharmacien, impact pour le patient et méthodes d'amélioration. Thèse d'exercice : Pharmacie : Université Grenoble 1, 2014. ,